Canadian Journal of Infectious Diseases and Medical Microbiology

Canadian Journal of Infectious Diseases and Medical Microbiology / 1992 / Article

Open Access

Volume 3 |Article ID 342127 | https://doi.org/10.1155/1992/342127

Wilson C Mertens, Vivien HC Bramwell, Peeyush K Lala, Diponkar Banerjee, Femida Gwadry-Sridhar, Walter Romano, "Continuous Indomethacin and Ranitidine with Interleukin-2 in Advanced Renal Carcinoma and Melanoma: A Preliminary Report", Canadian Journal of Infectious Diseases and Medical Microbiology, vol. 3, Article ID 342127, 5 pages, 1992. https://doi.org/10.1155/1992/342127

Continuous Indomethacin and Ranitidine with Interleukin-2 in Advanced Renal Carcinoma and Melanoma: A Preliminary Report

Abstract

Experimental work has shown that during the development of tumours, host macrophages can deactivate natural killer cells and suppress lymphokine-activated killer cell development, apparently through prostaglandin E2 production. Continuous indomethacin combined with interleukin (IL)-2 may totally eradicate experimental lung metastases. The preliminary results of a phase II trial of this combination are reported. Indomethacin 50 to 75 mg tid and ranitidine 150 mg bid are started at least one week before IL-2 and continued until disease progression. IL-2 is given by continuous infusion for three courses, each consisting of five days of treatment and six days of rest. IL-2 starting dose is 3.0x106 Cetus U/m2 for the first course with escalation to 4.5x106 and 6.0x106 U/m2 if toxicity allows. Pressor agents are not used. Thirty-two renal carcinoma patients were registered with seven withdrawing early. Two complete and three partial responses were seen for a response rate of (20%) for eligible and treated patients, or (16%) for all entered patients. Minor responses were seen in three patients. Twenty-five melanoma patients have been registered thus far and 18 have been eligible to proceed with IL-2 therapy. One complete and two partial responses have been seen. Two of these responses (one complete and one partial) were achieved on indomethacin and ranitidine alone, before starting IL-2.

Copyright © 1992 Hindawi Publishing Corporation. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


More related articles

 PDF Download Citation Citation
 Order printed copiesOrder
Views86
Downloads393
Citations

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.